An 'oblig­a­tion to re­bound': Bio­gen backs fur­ther away from ad­u­canum­ab as R&D team hunts down late-stage M&A op­por­tu­ni­ties

Stag­gered by a dis­as­ter for their Alzheimer’s drug ad­u­canum­ab, Bio­gen to­day took an­oth­er un­steady step back away from their big fo­cus on the mem­o­ry-wast­ing dis­ease as the CEO start­ed to talk up the di­ver­si­ty of its pipeline.

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER